In an article called, “Trump coaxes big promises from big pharma,” Jane is quoted on the recent announcements from pharma companies who are reducing certain prescription drug prices through the end of 2018. ‘This is not a policy, this is self-regulation – these are ad hoc agreements that are verbal and can change,’ Jane explained. Check out the in-depth analysis by Rebecca Trager.
Jane quoted in Royal Society of Chemistry journal on President Trump’s prescription drug pricing policy
By Jane Sarasohn-Kahn on 25 July 2018 in
I'm grateful to be part of the Duke Corporate Education faculty, sharing perspectives on the future of health care with health and life science companies. Once again, I'll be brainstorming the future of health care with a cohort of executives working in a global pharmaceutical company.
Thank you Aaron Strout for hosting our conversation on the Reaching Higher Podcast, now live on Apple, Spotify, and YouTube. We covered a lot of ground addressing health care and health citizenship, the growing prospects for our homes as our health hubs, and how our humanity is a key ingredient in health-making for all.
Jane joined host Dr. Geeta "Dr. G" Nayyar and colleagues to brainstorm the value of vaccines for public and individual health in this challenging environment for health literacy, health politics, and health citizen grievance. Click onto the Pfizer Value of Vaccines site and you can watch four episodes covering the challenges with adult vaccination, the employer and health plan member's journey to vaccination, reimbursement, and collaborating for proactive prevention.